Acute myeloid leukemias (AMLs) are overlapping hematological neoplasms associated with
rapid onset, progressive, and frequently chemo-resistant disease. At diagnosis, classification …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone
marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic …

Cancer driver mutations often show distinct temporal acquisition patterns, but the biological
basis for this, if any, remains unknown. RAS mutations occur invariably late in the course of …

Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a
strong and independent prognostic factor in acute myeloid leukemia (AML). However …

Flow cytometry immunophenotyping is essential for diagnosis, classification and monitoring
of clonal hematopoietic diseases, particularly of hematological malignancies and primary …

Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and
remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms …

Innate myeloid cell (IMC) populations form an essential part of innate immunity. Flow
cytometric (FCM) monitoring of IMCs in peripheral blood (PB) has great clinical potential for …

Introduction Monitoring of innate myeloid cells (IMC) is broadly applied in basic and
translational research, as well as in diagnostic patient care. Due to their immunophenotypic …

In recent years the volume and complexity of flow cytometry data has increased
substantially. This has led to a greater number of identifiable cell populations in a single …